Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor

• US 7,132,398 B2
• Filed: 05/06/2003
• Issued: 11/07/2006
• Est. Priority Date: 05/06/2003
• Status: Active Grant

• Current Assignee: Dendreon Pharmaceuticals, Inc. (Ya Fei Yuan,)
• Original Assignee: Dendreon Corporation (Bausch Health Cos., Inc.)
• Inventors: Vlasuk, George P.
• Primary Examiner(s): Wax, Robert A.
• Application Number:
  US10/431,629
• Publication Number:
  US 20040266672A1
• Time in Patent Office: 1,281 Days
• Field of Search: None
• US Class Current: 514/3.7
• CPC Class Codes: A61K 38/1767 from invertebrates
• CPC Class Codes: A61K 38/55 Protease inhibitors

Abstract

The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.

Claims

1. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of AcaNAPc2 (SEQ ID NO:

3).

4. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.

5. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.

6. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.

7. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.

8. The method of claim 1 wherein the hemorrhagic fever is caused by Ebola virus.

19. The method of claim 1 where the mammal is a human.

22. The method of claim 4 where the mammal is a human.

23. The method of claim 5 where the mammal is a human.

24. The method of claim 6 where the mammal is a human.

25. The method of claim 7 where the mammal is a human.

26. The method of claim 8 where the mammal is a human.

2. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of AcaNAPc2/proline (SEQ ID NO:

4).

9. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.

10. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.

11. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.

12. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.

13. The method of claim 2 wherein the hemorrhagic fever is caused by Ebola virus.

20. The method of claim 2 where the mammal is a human.

27. The method of claim 9 where the mammal is a human.

31. The method of claim 13 where the mammal is a human.

3. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of tissue factor pathway inhibitor (TFPI).

14. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.

15. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.

16. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.

17. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.

18. The method of claim 3 wherein the hemorrhagic fever is caused by Ebola virus.

21. The method of claim 3 where the mammal is a human.

32. The method of claim 14 where the mammal is a human.

33. The method of claim 15 where the mammal is a human.

34. The method of claim 16 where the mammal is a human.

35. The method of claim 17 where the mammal is a human.

36. The method of claim 18 wherein the mammal is a human.

28. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of AcaNAPc2 (SEQ ID No.:

3) effective to ameliorate symptoms of said fever.

29. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of AcaNAPc2/proline (SEQ ID No.:

4) effective to ameliorate symptoms of said fever.

30. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of tissue factor pathway inhibitor (TFPI) effective to ameliorate symptoms of said fever.